Clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension after COVID-19
https://doi.org/10.38109/2075-082X-2024-3-23-30
Abstract
The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus (SARS-CoV-2). This virus has many factors in its pathogenesis that affect the function of the right ventricle and pulmonary hemodynamics, which can negatively influence the clinical course of IPAH. According to the results of our study, the fact of getting over COVID-19 in patients with IPAH leads to some changes in laboratory and instrumental parameters. But no significant effect of COVID-19 on risk modification during the year was detected. This result can be explained by a combination of pathophysiological features of the pulmonary hypertension and the protective effect of constantly taken PAH-specific and anticoagulant therapy.
Keywords
idiopathic pulmonary hypertension,
pulmonary arterial hypertension,
COVID-19,
coronavirus,
pneumonia
Supporting agencies: The authors declare that there is no external funding for the study and publication of the article
About the Authors
A. M. Shariya
E.I. Chazov National Medical Research Center of cardiology
Russian Federation
Russian Federation
Archil M. Shariya, laboratory research assistant
121552; St. Academician Chazova, 15 a; Moscow
Z. S. Valieva
E.I. Chazov National Medical Research Center of cardiology
Russian Federation
Russian Federation
Zarina S. Valieva, Dr. Of Sci. (Med.), Senior Researcher
A.L. Myasnikov Institute of Clinical Cardiology; Department of Pulmonary Hypertension and Heart Diseases
121552; St. Academician Chazova, 15 a; Moscow
M. Yu. En
E.I. Chazov National Medical Research Center of cardiology
Russian Federation
Russian Federation
Margarita Yu. En, laboratory research assistant
A.L. Myasnikov Institute of Clinical Cardiology
121552; St. Academician Chazova, 15 a; Moscow
T. V. Martynyuk
E.I. Chazov National Medical Research Center of cardiology; N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tamila V. Martynyuk, Dr. Of Sci. (Med.), Head of the Department, Professor
A.L. Myasnikov Institute of Clinical Cardiology; Pulmonary Hypertension and Heart Diseases; Faculty of Continuing Professional Education; Department of Cardiology
121552; St. Academician Chazova, 15 a; Moscow
tel.: 8-495-414-64-50
References
1. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016. 37(1): 67-119. doi: 10.1093/eurheartj/ehv317
2. Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161:105850. doi: 10.1016/j.rmed.2019.105850
3. Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, Benton WW, Safford RE. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014 Nov;146(5):1263-1273. PMID: 24901386; PMCID: PMC4219341, ISSN 0012-3692, doi: 10.1378/chest.14-0193
4. World Health Organization WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 – 11 March 2020. [(accessed on 12 March 2020)]; https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
5. Gratsianskaya S.E., Demchenkova A.Yu., Martynyuk T.V., Veselova T.N., Ternovoy S.K. Case report of mild form of a new coronavirus infection in patient with idiopathic pulmonary hypertension. Kardiologiia. 2021;61(10):108-112. (in Russ.) doi: 10.18087/cardio.2021.10.n1405
6. Martynyuk T.V., Aleevskaya A.M., Rodnenkov O.V., Zorin A.V., Kasparova A.M., Nakonechnikov S.N., Chazova I.E. Management of patients with pulmonary arterial hypertension in the pandemic of a new coronavirus infection. Eurasian heart journal. 2020;(2):54-60. (In Russ.). doi: 10.38109/2225-1685-2020-2-54-60
7. Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020; 141(22):1733-5. doi: 10.1161/CIRCULATIONAHA.120.047008
8. Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518-36. doi: 10.1016/j.jacbts.2020.04.002
9. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619
10. Armand Mekontso Dessap, Florence Boissier, Cyril Charron, Emmanuelle Bégot et. al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016 May;42(5):862-870. doi: 10.1007/s00134-015-4141-2
11. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925
12. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. (2020). doi: 10.1101/2020.04.06.20050575
13. Nuche J., Pérez-Olivares C., Segura de la Cal T., Jiménez López-Guarch C., Arribas Ynsaurriaga F., Escribano Subías P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev. Esp. Cardiol. (2020). doi: 10.1016/j.recesp.2020.05.028
14. Horn E.M., Chakinala M., Oudiz R., Joseloff E., Rosenzweig E.B. Сould pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020;10. doi: 10.1177/2045894020922799
15. Cal T.S.d.l., Nuche J., López-Guarch C.J., Pérez-Olivares C., Velázquez M., Medrano F.L., Gude M.J.L., Charterina S.A., Ynsaurriaga F.A., Subías P.E. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020. doi: 10.1016/j.arbres.2020.06.004
16. Fida Charif, Fatima Dakroub, Imad Bou Akl, Mithum Kularatne, David Montani. Pulmonary arterial hypertension and COVID-19: Piecing the puzzle. Respiratory Medicine and Research Volume 84, November 2023, 101053. doi: 10.1016/j.resmer.2023.101053
17. Nuche J, Segura de la Cal T, Jiménez López Guarch C, López-Medrano F, Delgado CP-O, Ynsaurriaga FA, Delgado JF, Ibáñez B, Oliver E, Subías PE. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics. 2020;10(8):548. doi: 10.3390/diagnostics10080548
18. Hemnes A.R., Rathinasabapathy A., Austin E.A. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51:1702638. doi: 10.1183/13993003.02638-2017
19. Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879. doi: 10.1038/nm1267
20. Araz O. Current Pharmacological Approach to ARDS: The Place of Bosentan. Eurasian J.Med. 2020; 52:81-85. doi: 10.5152/eurasianjmed.2020.19218
21. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. PMID: 32329799. doi: 10.1001/jama.2020.6825
22. Kabir AA. Anticoagulation is the answer in treating noncritical COVID-19 patients. Open Med (Wars). 2021 Oct 5;16(1):1486-1492. PMID: 34703901; PMCID: PMC8494147. doi: 10.1515/med-2021-0354
Review
For citations:
Shariya A.M., Valieva Z.S., En M.Yu., Martynyuk T.V. Clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension after COVID-19. Systemic Hypertension. 2024;21(3):23-30. (In Russ.) https://doi.org/10.38109/2075-082X-2024-3-23-30
Views:
225
Email this article 